Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 140, 2020 - Issue 12
Submit an article Journal homepage
244
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events

Ryuji Yasumatsua Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6199-0341
ORCID Icon,
Mioko Matsuoa Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Takahiro Wakasakia Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanORCID Iconhttps://orcid.org/0000-0001-7736-9162
ORCID Icon,
Muneyuki Masudab Department of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan
,
Toranoshin Takeuchic Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
,
Tomomi Manakoc Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
,
Rina Jiromarua Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Ryutaro Uchia Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
Kazuki Hashimotoa Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
&
Takashi Nakagawaa Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
 show all
Pages 1043-1048 | Received 27 Jun 2020, Accepted 30 Jul 2020, Published online: 18 Aug 2020

References

  • Yasumatsu R, Nakashima T, Toh S, et al. Salvage of recurrent hypopharyngeal carcinoma after primary curative treatment. Acta Otolaryngol. 2013;133(10):1110–1116.
  • Yasumatsu R, Nakashima T, Komune S. Squamous cell carcinoma of the oropharynx: single-institution outcome analysis of patients treated with concurrent chemoradiotherapy. J Laryngol Otol. 2015;129(Suppl 2):S77–S82.
  • Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
  • Matsuo M, Yasumatsu R, Masuda M, et al. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol. 2020;101:104525.
  • Hori R, Shinohara S, Kojima T, et al. Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers (Basel). 2019;11(9):1317.
  • Okamoto I, Sato H, Kondo T, et al. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study. Acta Otolaryngol. 2019;139(10):918–925.
  • Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11(7):1927–1933.
  • Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
  • Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. 2017;28(7):1484–1494.
  • Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264–iv266.
  • Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
  • Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of Immune Related Adverse Events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
  • Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72(6):962–971.
  • Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–894.
  • Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145(2):479–485.
  • Ishihara H, Takagi T, Kondo T, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol. 2019;37:355 e321–355 e329.
  • Gauci ML, Lanoy E, Champiat S, et al. Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25(3):946–956.
  • Daste A, De-Mones E, Cochin V, et al. Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy. Oral Oncol. 2018;81:116–118.
  • Wakasaki T, Yasumatsu R, Uchi R, et al. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx. 2020;47(1):116–122.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.